FcγRIIIa gene polymorphism is associated with increased susceptibility to RA [47] and influences treatment outcomes in patients with RA or psoriatic arthritis treated with TNF-α blocking drugs and rituximab [48, 49]. The gene discussed is FCGR3A; the disease is rheumatoid arthritis.